{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:54:56Z","timestamp":1790848496296,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.lungcan.2024.107801","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T15:29:26Z","timestamp":1713972566000},"page":"107801","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Mirtazapine plus granisetron and dexamethasone for carboplatin-induced nausea and vomiting in patients with thoracic cancers: A prospective multicenter phase II trial"],"prefix":"10.1016","volume":"192","author":[{"given":"Hirotoshi","family":"Iihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamichi","family":"Iwai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2444-5974","authenticated-orcid":false,"given":"Yukiyoshi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Ohgino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiemi","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Masubuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0626-7908","authenticated-orcid":false,"given":"Hitoshi","family":"Kawazoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kawae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Aihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Fukunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1901-0535","authenticated-orcid":false,"given":"Mizuki","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junki","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2106-2123","authenticated-orcid":false,"given":"Akio","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"27","key":"10.1016\/j.lungcan.2024.107801_b0005","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1200\/JCO.2006.05.6382","article-title":"Delayed nausea and vomiting continue to reduce patients\u2019 quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment","volume":"24","author":"Bloechl-Daum","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2024.107801_b0010","first-page":"189","article-title":"Lung cancer. Biology and treatment options","volume":"1856","author":"Lemjabbar-Alaoui","year":"2015","journal-title":"Biochim. Biophys."},{"issue":"24","key":"10.1016\/j.lungcan.2024.107801_b0015","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO guideline update","volume":"38","author":"Hesketh","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"suppl 5","key":"10.1016\/j.lungcan.2024.107801_b0020","doi-asserted-by":"crossref","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","article-title":"2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and nausea and vomiting in advanced cancer patients","volume":"27","author":"Roila","year":"2016","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107801_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10147-020-01818-3","article-title":"Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis","volume":"26","author":"Aogi","year":"2021","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2024.107801_b0030","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Antiemesis. Version 1.2021. Available at https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf. [Last accessed September 26, 2023]."},{"issue":"3","key":"10.1016\/j.lungcan.2024.107801_b0035","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.lungcan.2014.03.017","article-title":"Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy","volume":"84","author":"Ito","year":"2014","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2024.107801_b0040","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.lungcan.2015.11.009","article-title":"Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer","volume":"90","author":"Kusagaya","year":"2015","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2024.107801_b0045","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00520-014-2339-4","article-title":"Usefulness of antiemetic therapy with aprepitant, palonosetron, and dexamethasone for lung cancer patients receiving cisplatin-based or carboplatin-based chemotherapy","volume":"23","author":"Kitazaki","year":"2015","journal-title":"Support. Care Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2024.107801_b0050","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1186\/s40064-016-3769-x","article-title":"Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, and aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapy","volume":"5","author":"Miya","year":"2016","journal-title":"SpringerPlus"},{"key":"10.1016\/j.lungcan.2024.107801_b0055","doi-asserted-by":"crossref","unstructured":"P. Patel, J.S. Leeder, M. Piquette\u2010Miller, L.L. Dupuis,Aprepitant and fosaprepitant drug interactions: A systematic review,Br. J. Clin. Pharmacol. 83 (10) (201) 2148\u20132162.","DOI":"10.1111\/bcp.13322"},{"issue":"5","key":"10.1016\/j.lungcan.2024.107801_b0060","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.suponc.2011.05.002","article-title":"Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial","volume":"9","author":"Navari","year":"2011","journal-title":"J. Su. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107801_b0065","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1756-9966-28-131","article-title":"Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting","volume":"28","author":"Tan","year":"2009","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2024.107801_b0070","first-page":"3439707","article-title":"The Efficacy, Safety, and Cost Benefit of Olanzapine versus Aprepitant in Highly Emetogenic Chemotherapy: A Pilot Study from South India","author":"Babu","year":"2016","journal-title":"Chemother. Res. Pract."},{"issue":"2","key":"10.1016\/j.lungcan.2024.107801_b0075","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting","volume":"375","author":"Navari","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.lungcan.2024.107801_b0080","doi-asserted-by":"crossref","first-page":"e1066","DOI":"10.1002\/onco.13772","article-title":"Low-dose olanzapine plus granisetron and dexamethasone for carboplatin-induced nausea and vomiting in patients with thoracic malignancies: a prospective multicenter phase II trial","volume":"26","author":"Sakai","year":"2021","journal-title":"Oncologist"},{"issue":"Suppl 10","key":"10.1016\/j.lungcan.2024.107801_b0085","first-page":"28","article-title":"In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug","volume":"58","author":"Bymaster","year":"1997","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.lungcan.2024.107801_b0090","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1527-3458.2001.tb00198.x","article-title":"A review of the pharmacological and clinical profile of mirtazapine","volume":"7","author":"Anttila","year":"2001","journal-title":"CNS. Drug Rev."},{"issue":"3","key":"10.1016\/j.lungcan.2024.107801_b0095","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0165-0327(98)00224-9","article-title":"Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression","volume":"51","author":"Fawwcett","year":"1998","journal-title":"J. Affective Dis."},{"issue":"5","key":"10.1016\/j.lungcan.2024.107801_b0100","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/00019442-200209000-00007","article-title":"Mirtazapine vs. Paroxetine Study Group. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients","volume":"10","author":"Schatzberg","year":"2002","journal-title":"Am. J. Geriatr. Psychiatry"},{"issue":"5","key":"10.1016\/j.lungcan.2024.107801_b0105","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/JCP.0000000000000183","article-title":"Does mirtazapine interfere with naturalistic diabetes treatment?","volume":"34","author":"Song","year":"2014","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.lungcan.2024.107801_b0110","first-page":"451","article-title":"Comparison of mirtazapine and olanzapine on nausea and vomiting following anthracycline-cyclophosphamide chemotherapy regimen in patients with breast cancer","volume":"19","author":"Maleki","year":"2020","journal-title":"Iran J. Pharm. Res."},{"issue":"3","key":"10.1016\/j.lungcan.2024.107801_b0115","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.21873\/anticanres.16277","article-title":"Effect of Mirtazapine for the Prevention of Nausea and Vomiting in Patients with Thoracic Cancer Receiving Platinum-based Chemotherapy","volume":"43","author":"Kinomura","year":"2023","journal-title":"Anticancer Res."},{"issue":"9","key":"10.1016\/j.lungcan.2024.107801_b0120","first-page":"3939","article-title":"A randomized controlled non-inferiority study comparing the antiemetic effect between intravenous granisetron and oral azasetron based on estimated 5-HT3 receptor occupancy","volume":"32","author":"Endo","year":"2012","journal-title":"Anticancer Res."},{"issue":"9","key":"10.1016\/j.lungcan.2024.107801_b0125","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00520-009-0737-9","article-title":"Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: Analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy","volume":"18","author":"Hesketh","year":"2018","journal-title":"Support. Care Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2024.107801_b0130","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00520-010-0899-5","article-title":"Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy","volume":"19","author":"Warr","year":"2011","journal-title":"Support. Care Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2024.107801_b0135","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00520-010-1073-9","article-title":"Chemotherapy-induced nausea and vomiting in daily clinical practice: A community hospital-based study","volume":"20","author":"Hilarius","year":"2012","journal-title":"Support. Care Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2024.107801_b0140","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/cas.12146","article-title":"Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis","volume":"104","author":"Sekine","year":"2013","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107801_b0145","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00520-017-3857-7","article-title":"Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?- Systematic review and meta-analysis","volume":"26","author":"Jordan","year":"2018","journal-title":"Support. Care Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2024.107801_b0150","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1634\/theoncologist.2019-0292","article-title":"A nationwide, multicenter registry study of antiemesis for carboplatin-based chemotherapy-induced nausea and vomiting in Japan","volume":"25","author":"Iihara","year":"2020","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.lungcan.2024.107801_b0155","first-page":"919","article-title":"Metoclopramide: a dopamine receptor antagonist","volume":"41","author":"DiPalma","year":"1990","journal-title":"Am. Fam. Physician"},{"issue":"10","key":"10.1016\/j.lungcan.2024.107801_b0160","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1056\/NEJMp0911494","article-title":"The missing voice of patients in drug-safety reporting","volume":"362","author":"Basch","year":"2010","journal-title":"N. Engl. J. Med"},{"issue":"11","key":"10.1016\/j.lungcan.2024.107801_b0165","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1470-2045(06)70910-X","article-title":"Patient versus clinician symptom reporting using the national cancer institute common terminology criteria for adverse events: results of a questionnaire-based study","volume":"7","author":"Basch","year":"2006","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2024.107801_b0170","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s00520-009-0613-7","article-title":"Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02","volume":"17","author":"Shimozuma","year":"2009","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.lungcan.2024.107801_b0175","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41416-023-02493-7","article-title":"Dexamethasone-sparing on days 2\u20134 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)","volume":"130","author":"Minatogawa","year":"2024","journal-title":"Br J Cancer."},{"issue":"3","key":"10.1016\/j.lungcan.2024.107801_b0180","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ygyno.2020.01.004","article-title":"Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study","volume":"56","author":"Iihara","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2024.107801_b0185","doi-asserted-by":"crossref","first-page":"e1066","DOI":"10.1002\/onco.13772","article-title":"Low-Dose Olanzapine Plus Granisetron and Dexamethasone for Carboplatin-Induced Nausea and Vomiting in Patients with Thoracic Malignancies: A Prospective Multicenter Phase II Trial","volume":"26","author":"Sakai","year":"2021","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.lungcan.2024.107801_b0190","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00280-019-03868-5","article-title":"Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting","volume":"84","author":"Tanaka","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"2","key":"10.1016\/j.lungcan.2024.107801_b0195","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","article-title":"Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Hashimoto","year":"2020","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2024.107801_b0200","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10637-020-00903-8","article-title":"Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: An open-label, randomized, multicenter phase III trial","volume":"38","author":"Cao","year":"2020","journal-title":"Invest. New Drugs"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224003350?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224003350?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T13:09:20Z","timestamp":1720789760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500224003350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":40,"alternative-id":["S0169500224003350"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107801","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mirtazapine plus granisetron and dexamethasone for carboplatin-induced nausea and vomiting in patients with thoracic cancers: A prospective multicenter phase II trial","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107801","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107801"}}